Vaccine Schedule Chart Reveals No Trials vs Saline Placebo + Insufficient Trial Durations to Assess Adverse Effects; Consider Refraining from Vaccinating Your Children
News Article: Childhood Vaccines and Placebo-Controlled Trials
A chart detailing every vaccine on the routine childhood immunization schedule has been produced by the Informed Consent Action Network (ICAN), shedding light on the use of placebo-controlled trials in the development of these vaccines.
The chart, titled "no-placebo-101823.pdf" and available at https://openvaers.com/component/acym/archive/66-icans-no-placebo-chart, lists the brand and manufacturer for each vaccine, the number of doses recommended, and the age at which each vaccine is administered.
However, the chart reveals a significant finding: none of the vaccines on the childhood schedule were tested against an inert saline placebo during clinical trials. Instead, they were typically compared to existing vaccines or non-inert comparators.
This practice is not uncommon in the field of vaccinology, but recent policy changes suggest that new vaccines will undergo safety testing in placebo-controlled trials prior to licensure, a shift from past practices.
Regarding clinical trial duration, these trials often last several months to about a year or more, which is generally deemed sufficient by regulatory agencies to detect common adverse events and evaluate efficacy. However, the chart indicates that a true risk versus benefit assessment cannot be made for the vaccines on the childhood schedule, as longer-term harms might not be fully captured in these typical trial durations.
The chart was produced at the behest of the Informed Consent Action Network (ICAN) and was not produced by the manufacturer of any of the vaccines on the childhood schedule, nor by the government or a regulatory body. It is important to note that the chart does not contain advertisements for any vaccine manufacturer or product.
The document "no-placebo-101823.pdf" is 478 KB in size.
This information underscores the importance of post-licensure monitoring for capturing rare or long-term adverse outcomes. As vaccines play a critical role in public health, understanding their development and safety profile is crucial for informed decision-making.
- In the practice of vaccinology, a shift towards using placebo-controlled trials in the safety testing of new vaccines before licensure has been suggested, marking a departure from past norms, highlighting the significance of post-licensure monitoring for capturing rare or long-term adverse outcomes.
- The data gathered by the Informed Consent Action Network (ICAN) in their chart, titled "no-placebo-101823.pdf", indicates that a true risk versus benefit assessment for medical-conditions related to vaccines on the childhood schedule cannot be fully made due to the typical trial durations, as longer-term harms might not be completely captured.
